{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-322160","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2026-07-29T11:19:48+00:00","discovered_at":"2026-07-29T11:25:00.257670+00:00","generated_at":"2026-07-29T11:25:27.504114+00:00","sec_items":["1.01","3.03","5.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Synlogic to merge with Caldera Therapeutics; Synlogic shareholders to own ~2.3% of combined company","bullets":["Merger with Caldera; Synlogic shareholders to receive shares in new parent, owning ~2.3% on fully diluted basis.","Caldera equityholders (pre-money) to own ~62.8%; concurrent $278M financing investors own ~34.9%.","Synlogic valued at $18M (assuming $6M net cash); Caldera valued at $500M.","Support agreements from 50.9% of Synlogic stockholders and 72.6% of Caldera stockholders.","Warrant amendments reduce exercise price to $0.70/share and remove cash redemption right."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-322160","json":"https://secwatch.observer/filing/0001193125-26-322160.json","markdown":"https://secwatch.observer/filing/0001193125-26-322160.md","text":"https://secwatch.observer/filing/0001193125-26-322160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000119312526322160/0001193125-26-322160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000119312526322160/d91010d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T11:25:27.504114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}